Douglas Scharre
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
The study will use structural and functional MRIs, daTscans, fluorodeoxyglucose (FDG) PET scans, Amyvid PET scans, polysomnographs, neuropsychological testing, cerebrospinal fluid in willing participants to distinguish between a diagnosis of Alzheimer's disease, Lewy Body dementia, and Parkinson's Disease. All subjects will have a clinical evaluation, physical examination including vital signs and orthostatic blood pressures and pulses, neurological examination including UPDRS evaluation, genetic blood sample collection, neuropsychological testing, polysomnogram, and neuroimaging. The study pa…
Inclusion Criteria: * Subjects must meet the standard clinical criteria of the syndromes of interest * All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10. * Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment. * Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week. * Subjects must have visual and aud…
A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT
A brain scan to to measure the extent of amyloid deposition
a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
Overnight sleep study
Clinical assessments include cognitive, behavioral, and motor evaluations
Arctuva estimate
Verify or correct the compensation shown for this listing.